Shandong Suncadia Medicine Co., Ltd. was established in June 2018, as a wholly-owned subsidiary of Hengrui Pharmaceutical, and strives to build another innovative research and development and industrialization base with international standards for Hengrui Pharmaceutical, and realize the complete drug research and development chain from molecular evaluation to the research and development of apis and preparations, production transformation, and declaration business. Shandong Shengdi has undertaken the research and development and production of many innovative drug products in the field of anti-HIV, anti-tumor, diabetes and cardiovascular. Shandong Shengdi focuses on the layout of small molecule innovative drugs, and a number of class 1 innovative drug projects have been approved for clinical use.

Tags

Neoplasms

Endocrinology and Metabolic Disease

Skin and Musculoskeletal Diseases

Small molecule drug

Proteolysis-targeting chimeras

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	6
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	12
Antibody drug conjugate (ADC)	1
Proteolysis-targeting chimeras	1

Top 5 Target	Count

ER(Estrogen receptors)	2
HER3(Receptor tyrosine-protein kinase erbB-3)	1
CDK4 x CDK6(Cyclin-dependent kinase 4 x Cyclin-dependent kinase 6)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
DPP-4 x PRKAB1 x SGLT2(Dipeptidyl peptidase IV x Protein kinase AMP-activated non-catalytic subunit beta 1 x Sodium/glucose cotransporter 2)	1

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 01 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

Phase 1

Phase 2

NDA/BLA

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Henagliflozein Proline/Metformin Hydrochloride ( PRKAB1 x SGLT2 )	Diabetes Mellitus, Type 2 More	Approved
Henagliflozein Proline/Retagliptin Phosphate/Metformin Hydrochloride ( DPP-4 x PRKAB1 x SGLT2 )	Diabetes Mellitus, Type 2 More	NDA/BLA
Retgliptin/Metformin ( DPP-4 )	Diabetes Mellitus, Type 2 More	NDA/BLA
HRS-7535 ( GLP-1R )	Obesity More	Phase 2
HRS-1780	Chronic Kidney Diseases More	Phase 2

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis